Selective targeting of NURR1 in alzheimer's disease
Active Grant Awarded
- Award ID
- R56AG100922
- Recipient
-
Saint Louis University UEI JNBLLTBTLLD8
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $541,009
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 21% complete
- Place of performance
- St. Louis, MO 63104, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Institute on Aging awarded Saint Louis University a $541,009 grant on September 9, 2026, under the Aging Research program (CFDA 93.866), to fund research on selectively targeting NURR1 for Alzheimer's disease. The project seeks potent and selective NURR1 agonists. It builds on preliminary work identifying compound (97) and its analog SLUPP-1173, which bind NURR1 specifically, activate its function, reduce IL-1B expression in treated microglial cells, and improve memory retention in a mouse model of Alzheimer's disease. The stated objective is to improve the potency, specificity, and pharmacological activity of these compounds. The award is classified as a grant with $541,009 obligated. Performance runs from the September 9, 2026 award date to an ultimate completion date of August 31, 2027, with place of performance in St. Louis, Missouri 63104. The program's stated mission is to support biomedical and behavioral research in aging, with emphasis on preventing and treating Alzheimer's disease and related dementias.
Description
- Abstract
- Alzheimer's disease (ad), a progressive neurodegenerative disease that saps an individual's ability to recall information, perform activities of daily living, and engage with the world around them, has a high and constantly increasing global prevalence. The disease is the sixth leading cause of death in the U.S. With limited efficacious treatment options available. A critical need for improved pharmacological therapies exists if we are to bend the curve on ad outcomes. A promising strategy towards treatment of ad lies in targeting neuroinflammation mechanisms. Recent studies led to the discovery that the orphan nuclear receptor (NR) NURR1 (NR4A2) is a promising target for ad and other neurodegenerative diseases. NURR1 is a neuroprotective transcription factor and anti-inflammatory regulator that is highly expressed in the brain-especially in neurons. In microglia and astrocytes, NURR1 acts as negative regulator of nfkb-regulated inflammatory genes. Recently identified NURR1 agonists either have poor specificity, weak potency, contain scaffolds that limited future modifications for structure-activity relationship (SAR) efforts, lack data for blood-brain barrier (BBB) penetrance or are deficient in pharmacokinetic (PK) data. Thus, a crucial need to find potent and selective NURR1 agonists exists in order to probe pharmacological NURR1 modulation as a therapeutic strategy for ad. To address this, in our preliminary work, we found compound (97) and its analog slupp-1173 that bind specifically to NURR1, activate NURR1 function, and have satisfactory PK properties. In addition, both compounds have good brain penetration, reduce IL-1B expression in microglial cells treated with amyloid beta (AB1-42) or LPS, and improve memory retention in a mouse model of ad. However, work remains to improve the potency, specificity, and pharmacological activity of these compounds. We hypothesize that optimized NURR1 agonists are effective agents for reducing neuroinflammation and will hold utility for the treatment of ad, and potentially other neurodegenerative disorders. To test this hypothesis, we will focus on two specific aims-aim 1: develop and optimize NURR1 agonists, and aim 2: define the cellular anti-inflammatory activity and pharmacological activity of action of NURR1 agonists on cognitive impairment. In aim 1, we will optimize synthetic NURR1 agonists that can progress to our in vivo mouse model of ad. In aim 2, NURR1 agonists will be tested for their ability to reduce the expression of inflammatory genes in microglial cells and astrocytes. Furthermore, the best NURR1 agonist analogs will be administered to male and female 5XFAD mouse model of ad and wild-type mouse (C57BL/6). Learning, memory and executive function will be assessed via a series of behavioral tests. Inflammation in the brain will also be assessed. Our results are anticipated to provide novel and transformative molecular insights into ad pathogenesis by establishing the specific role of NURR1 while offering a target for ad therapeutic intervention with NURR1 agonists.
Quick answers
Who received award R56AG100922?
R56AG100922 was awarded to Saint Louis University by National Institute on Aging (National Institutes of Health) on September 9, 2026.
How much is award R56AG100922 worth?
$541,009 has been obligated on R56AG100922.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award